PhD Sarah Haile
Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
Samaras P, Stenner-Liewen F, Knuth A, Stahel R, Stussi G, Schanz U, Honegger H, Mischo A, Petrausch U, Buset E, Haile S, Siciliano R, Blickenstorfer M, Renner C. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Ann Hematol 2010; 90:89-94.
Aug 13, 2010Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
Aug 13, 2010Ann Hematol 2010; 90:89-94
Samaras Panagiotis, Stenner-Liewen Frank, Knuth Alexander, Stahel Rolf A, Stussi Georg, Schanz Urs, Honegger Hanspeter, Mischo Axel, Petrausch Ulf, Buset Elefteri M, Haile Sarah, Siciliano Raffaele Daniele, Blickenstorfer Marcel, Renner Christoph
Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP
Samaras P, Stenner-Liewen F, Knuth A, Zweifel M, Mischo A, Meisel A, Siciliano R, Schaefer N, Petrausch U, Haile S, Heider H, Renner C. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol 2010; 89:783-7.
Mar 5, 2010Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP
Mar 5, 2010Ann Hematol 2010; 89:783-7
Samaras Panagiotis, Stenner-Liewen Frank, Knuth Alexander, Zweifel Martin, Mischo Axel, Meisel Alexander, Siciliano Raffaele Daniele, Schaefer Niklaus G, Petrausch Ulf, Haile Sarah, Heider Helen, Renner Christoph
Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy
Petrausch U, Renner C, Mischo A, Hany T, Knuth A, Soyka J, Veit-Haibach P, Haile S, Samaras P, Schäefer N. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol 2010; 21:1694-8.
Feb 5, 2010Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy
Feb 5, 2010Ann Oncol 2010; 21:1694-8
Petrausch U, Renner C, Mischo A, Hany T F, Knuth A, Soyka J D, Veit-Haibach P, Haile Sarah, Samaras P, Schäefer N G
Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches
Land S, Ritter M, Costantino J, Julian T, Cronin W, Haile S, Wolmark N, Ganz P. Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:5113-20.
Nov 10, 2007Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches
Nov 10, 2007Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:5113-20
Land Stephanie R, Ritter Marcie W, Costantino Joseph P, Julian Thomas B, Cronin Walter M, Haile Sarah, Wolmark Norman, Ganz Patricia A
Is sentinel node biopsy necessary in conservatively treated DCIS?
Julian T, Land S, Fourchotte V, Haile S, Fisher E, Mamounas E, Costantino J, Wolmark N. Is sentinel node biopsy necessary in conservatively treated DCIS?. Annals of surgical oncology 2007; 14:2202-8.
Aug 1, 2007Is sentinel node biopsy necessary in conservatively treated DCIS?
Aug 1, 2007Annals of surgical oncology 2007; 14:2202-8
Julian Thomas B, Land Stephanie R, Fourchotte Virginie, Haile Sarah, Fisher Edwin R, Mamounas Eleftherios P, Costantino Joseph P, Wolmark Norman